2021 CMSC Annual Meeting

Tag: 7817Disease-modifying therapyWilliam L Conte, MD, MS*, Comprehensive MS Center, Methodist Hospitals, Merrillville, IN

Late Breaking-Disease-modifying therapy

B-Cell Depleters Attenuate the Humoral Response to Sars-Cov-2 Vaccines in Multiple Sclerosis Patients: A Case-Control Study

Background: B-cell depleting agents are FDA approved for the treatment of RRMS (ocrelizumab (OCR) and ofatumumab (OFA)) and PPMS...

Read More